{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:20:22Z","timestamp":1783948822688,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.msard.2019.06.035","type":"journal-article","created":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T02:08:23Z","timestamp":1561774103000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"35","author":[{"given":"Chuan","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-9051","authenticated-orcid":false,"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Tao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Shi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.06.035_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2019.06.035_bib0002","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2019.06.035_bib0003","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2019.06.035_bib0004","first-page":"383","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev."},{"issue":"7","key":"10.1016\/j.msard.2019.06.035_bib0005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamaneurol.2014.940","article-title":"Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2019.06.035_bib0006","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"9451","key":"10.1016\/j.msard.2019.06.035_bib0007","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"Pt 7","key":"10.1016\/j.msard.2019.06.035_bib0008","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.msard.2019.06.035_bib0009","first-page":"493","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev."},{"issue":"6","key":"10.1016\/j.msard.2019.06.035_bib0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2019.06.035_bib0011","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"14","author":"Peschl","year":"2017","journal-title":"J. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2019.06.035_bib0012","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14737175.2017.1282821","article-title":"Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases","volume":"17","author":"Pilch","year":"2017","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.msard.2019.06.035_bib0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"Pt 5","key":"10.1016\/j.msard.2019.06.035_bib0014","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2019.06.035_bib0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2019.06.035_bib0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2019.06.035_bib0017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2013.09.010","article-title":"A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission","volume":"57","author":"Veszeli","year":"2014","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2019.06.035_bib0018","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819302810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819302810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:39Z","timestamp":1761900339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819302810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":18,"alternative-id":["S2211034819302810"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.06.035","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}